1369405-80-0

Basic information

• Product Name: (3R,4R,6R)-3,4-bis(benzyloxy)-6-((benzyloxy)methyl)-5,5-difluorotetrahydro-2H-pyran-2-one
• Synonyms: (3R,4R,6R)-3,4-bis(benzyloxy)-6-((benzyloxy)methyl)-5,5-difluorotetrahydro-2H-pyran-2-one
• CAS NO: 1369405-80-0
• Molecular Weight: 468.497
• Mol File: 1369405-80-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (3R,4R,6R)-3,4-bis(benzyloxy)-6-((benzyloxy)methyl)-5,5-difluorotetrahydro-2H-pyran-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,4R,6R)-3,4-bis(benzyloxy)-6-((benzyloxy)methyl)-5,5-difluorotetrahydro-2H-pyran-2-one(1369405-80-0)
• EPA Substance Registry System: (3R,4R,6R)-3,4-bis(benzyloxy)-6-((benzyloxy)methyl)-5,5-difluorotetrahydro-2H-pyran-2-one(1369405-80-0)

Safety Data

• Hazardous Substances Data: 1369405-80-0(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 1125-88-8 benzaldehyde dimethyl acetal 
• 48149-72-0 (2S,3R,4S,5R,6R)-2-Allyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol 
• 634181-78-5 (R)-4-((R)-1-(benzyloxy)-2,2-difluorobut-3-en-1-yl)-2,2-dimethyl-1,3-dioxolane 
• 1369405-70-8 (2R,3R)-3-(benzyloxy)-1-((tert-butyldimethylsilyl)oxy)-4,4-difluorohex-5-en-2-ol 
• 1369405-79-7 (2S,3R,5R)-2,3,6-tris(benzyloxy)-4,4-difluorohexane-1,5-diol 
• 1369405-77-5 (2R,4R,5S)-1,4,5-tris(benzyloxy)-6-((tert-butyldimethylsilyl)oxy)-3,3-difluorohexan-2-ol 
• 1369405-76-4 C₂₆H₃₈F₂O₅Si 
• 1369405-75-3 (((2S,3R)-2,3-bis(benzyloxy)-4,4-difluorohex-5-en-1-yl)oxy)(tert-butyl)dimethylsilane 
• 1369405-74-2 (2S,3R)-3-(benzyloxy)-1-((tert-butyldimethylsilyl)oxy)-4,4-difluorohex-5-en-2-ol 
• 1369405-73-1 C₁₃H₁₆F₂O₃ 
• 1369405-72-0 (2S,3R)-3-(benzyloxy)-4,4-difluorohex-5-ene-1,2-diyl diacetate 
• 1369405-71-9 (S)-2-((R)-1-(benzyloxy)-2,2-difluorobut-3-en-1-yl)oxirane 
• 1005768-69-3 (2R,3R)-3-O-benzyl-4,4-difluoro-5-hexene-1,2,3-triol 

Downstream Products

• 1369406-03-0 C₄₂H₄₁ClF₂O₆ 
• 1181680-69-2 (2R,4R,5S,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)-3,3-difluorotetrahydro-2H-pyran 
• 1181680-71-6 (2S,3R,4R,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-5,5-difluoro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol 
• 1369405-81-1 (2R,4R,5S,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(4-chloro-3-(4-isopropoxybenzyl)phenyl)-3,3-difluorotetrahydro-2H-pyran 
• 1369405-82-2 (2R,4R,5S,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(4-chloro-3-(4-propoxybenzyl)phenyl)-3,3-difluorotetrahydro-2H-pyran 
• 1369405-83-3 (2R,4R,5S,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(4-chloro-3-(4-methoxybenzyl)phenyl)-3,3-difluorotetrahydro-2H-pyran 
• 1181680-59-0 (2R,4R,5S,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(4-chloro-3-(4-ethylbenzyl)phenyl)-3,3-difluorotetrahydro-2H-pyran 
• 1369405-84-4 (2R,4R,5S,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(4-chloro-3-(4-methylbenzyl)phenyl)-3,3-difluorotetrahydro-2H-pyran 
• 1369405-85-5 (2R,4R,5S,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(3-(4-ethoxybenzyl)-4-methylphenyl)-3,3-difluorotetrahydro-2H-pyran 
• 1369405-86-6 (2R,4R,5S,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(3-(4-isopropoxybenzyl)-4-methylphenyl)-3,3-difluorotetrahydro-2H-pyran 
• 1181681-87-7 (2S,3R,4R,6R)-2-(4-chloro-3-(4-isopropoxybenzyl)phenyl)-5,5-difluoro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol 
• 1369405-54-8 (2S,3R,4R,6R)-2-(4-chloro-3-(4-propoxybenzyl)phenyl)-5,5-difluoro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol 
• 1181681-54-8 (2S,3R,4R,6R)-2-(4-chloro-3-(4-methoxybenzyl)phenyl)-5,5-difluoro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol 
• 1181680-61-4 (2S,3R,4R,6R)-2-(4-chloro-3-(4-ethylbenzyl)phenyl)-5,5-difluoro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol 

Relevant articles and documents

5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors

(2S,3R,4R,5S,6R)-2-Aryl-5,5-difluoro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diols and (2S,3R,4R,5S,6R)-2-aryl-5-fluoro-5-methyl-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diols were discovered as dual inhibitors of sodium glucose co-transporter proteins (

BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS

The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.